SMMT - Summit Therapeutics Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Market Current Price & Safety Score Price: 15.77 USD StockBonds Safety Grade: D Altman Z-Score (Bankruptcy Risk): 38.56 StockBond Score: -2.99 Company Description Summit Therapeutics Inc is a biopharmaceutical firm dedicated to discovering developing and commercializing therapeutic solutions primarily targeting infectious diseases across the United States and Latin America The companys clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection CDI Its flagship product candidate ridinilazole is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI Beyond its lead asset Summit Therapeutics is also progressing SMT738 designed to combat multidrugresistant infections notably carbapenemresistant Enterobacteriaceae CRE Additionally its DDS04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria Established in 2003 the company maintains its headquarters in Cambridge Massachusetts